RainSure Announces Completion of ￥10M Series B1 Funding Round

(VCBeat) Feb. 23, 2021 -- Recently, Suzhou-based RainSure Scientific Co., Ltd. ("RainSure") announced in Suzhou Industrial Park that it has completed a Series B1 financing of tens of millions, led by Zero2IPO Asset Management, with participation from Kaitai Capital, and the existing investors Future Capital and Volcanics Venture. Benchu Capital acts as the exclusive financial advisor.

The funds are earmarked for the R&D and registration of the digital PCR kit for in vitro diagnostics, the construction of the GMP compliant manufacturing facility, the optimization of the domestic sales team and distributor network, and the consolidation of the overseas sales channels established during the covid-19 pandemic. 

Prior to this, RainSure has secured over 100 million yuan in three rounds of investment from ZhenFund, Volcanics Venture, Future Capital and YuanBio Venture Capital.

Founded in October 2017 with the mission of innovation, intelligent manufacturing and serving for health, RainSure is committed to promoting the innovative application of leading technologies including digital PCR in the fields of scientific research, in vitro diagnosis, inspection, and quarantine.

At present, RainSure's products cover digital PCR systems, microfluidic solutions, and in vitro diagnostic reagents. It has set up an R&D and production base in Suzhou Industrial Park, which obtained the ISO13485 certification.

Zero2IPO Asset Management provides industrial strategy and medium & long-term asset management investment services for listed companies and family enterprises. Currently, it has managed dozens of strategic funds and family funds of listed companies over 20 billion yuan, mainly investing in growth-stage companies in healthcare, consumption upgrading, intelligent manufacturing, culture and entertainment, education and other fields.

Kaitai Capital, founded in 2009, is a professional investment management organization that mainly engaged in innovative investment, industrial investment, and wealth management business. Fields of investment include biopharma, healthcare services, agriculture tech, consumer business, digital technology and etc. Currently, the asset under management of Kaitai Capital has reached 50 billion RMB (USD$7.2B).